Sagopilone (ZK-EPO): From a natural product to a fully synthetic clinical development candidate

Expert Opinion on Investigational Drugs

Volumn 17, Issue 11, 2008, Pages 1735-1748

  Klar, Ulrich ^a   Hoffmann, Jens ^a   Giurescu, Marius ^a  

^a BAYER PHARMA AG   (Germany)

Author keywords

Epothilone; Natural product; Sagopilone; Total synthesis; ZK EPO

Indexed keywords

9,10 DIDEHYDRO 26 TRIFLUOROISOXAZOLE EPOTHILONE D; 9,10 DIDEHYDROEPOTHILONE D; ANTHRACYCLINE DERIVATIVE; BMS 310705; BMS 753493; CAPECITABINE; CARBOPLATIN; CISPLATIN; CYTOTOXIC AGENT; DACARBAZINE; EPOTHILONE A; EPOTHILONE B; EPOTHILONE D; EPOTHILONE DERIVATIVE; GEMCITABINE; IXABEPILONE; KOS 1584; KOS 1803; PACLITAXEL; PLATINUM COMPLEX; PREDNISONE; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P53; SAGOPILONE; TAXANE DERIVATIVE; TEMOZOLOMIDE; UNCLASSIFIED DRUG; VERAPAMIL; ZK EPO;

ALOPECIA; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER CELL CULTURE; CANCER INHIBITION; CLINICAL STUDY; CLINICAL TRIAL; DIARRHEA; DRUG DESIGN; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG RESEARCH; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; DRUG TOLERABILITY; GLIOMA; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LUNG CANCER; MALIGNANT NEOPLASTIC DISEASE; MICROTUBULE ASSEMBLY; MONOTHERAPY; NEUROPATHY; NEUTROPENIA; NONHUMAN; PERIPHERAL NEUROPATHY; PROCESS OPTIMIZATION; REVIEW; SIGNAL TRANSDUCTION; SOLID TUMOR; STRUCTURE ANALYSIS; TREATMENT OUTCOME;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BENZOTHIAZOLES; BIOLOGICAL PRODUCTS; DRUG EVALUATION, PRECLINICAL; EPOTHILONES; HUMANS; TUBULIN;

EID: 54949105468     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.17.11.1735     Document Type: Review

References (86)

1. Fuchs DA, Johnson RK. Cytologic evidence that taxol, an antineoplastic agent from Taxus brevifolia, acts as a mitotic spindle poison. Cancer Treat Rep 1978;62:1219-22
2. Horwitz SB. Mechanism of action of taxol. Trends Pharmacol Sci 1992;13:134-6
3. Jordan MA, Wendell K, Gardiner S, et al. Mitotic block induced in HeLa cells by low concentrations of paclitaxel (Taxol) results in abnormal mitotic exit and apoptotic cell death. Cancer Res 1996;56:816-25
4. Wahl AF, Donaldson KL, Fairchild C, et al. Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis. Nat Med 1996;2:72-9
5. Bollag DM, McQueney PA, Zhu J, et al. Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action. Cancer Res 1995;55:2325-33
6. Gerth K, Bedorf N, Höfle G, et al. Epothilons A and B: antifungal and cytotoxic compounds from Sorangium cellulosum (Myxobacteria). Production, physico-chemical and biological properties. J Antibiot Tokyo 1996;49:560-3
7. Kowalski RJ, Giannakakou P, Gunasekera SP, et al. The microtubule-stabilizing agent discodermolide competitively inhibits the binding of paclitaxel (Taxol) to tubulin polymers, enhances tubulin nucleation reactions more potently than paclitaxel, and inhibits the growth of paclitaxel-resistant cells. Mol Pharmacol 1997;52:613-22
8. Liu J, Towle MJ, Cheng H, et al. In vitro and in vivo anticancer activities of synthetic (-)-laulimalide, a marine natural product microtubule stabilizing agent. Anticancer Res 2007;27:1509-18
9. Long BH, Carboni JM, Wasserman AJ, et al. Eleutherobin, a novel cytotoxic agent that induces tubulin polymerization, is similar to paclitaxel (Taxol). Cancer Res 1998;58:1111-5
10. Kingston DG. A natural love of natural products. J Org Chem 2008;73:3975-84
11. Höfle G, Steinmetz H, Bedorf N, et al. Epothilone A and B-novel 16-membered macrolides with cytotoxic activity: isolation, crystal structure, and conformation in solution. Angew Chem Int Ed Engl 1996;35:1567-9
12. Melton L. Cellular pump changes prospect of disease resistance. Lancet 2001;357:1186
13. ten Tije AJ, Verweij J, Loos WJ, Sparreboom A. Pharmacological effects of formulation vehicles: implications for cancer chemotherapy. Clin Pharmacokinet 2003;42:665-85
14. Ardavanis A, Tryfonopoulos D, Yiotis I, et al. Non-allergic nature of docetaxel-induced acute hypersensitivity reactions. Anticancer Drugs 2004;15:581-585
15. Bart J, Groen HJM, Hendrikse NH, et al. The blood-brain barrier and oncology: new insights into function and modulation. Cancer Treat Rev 2000;26:449-62
16. Kniesel U, Wolburg H. Tight junctions of the blood-brain barrier. Cell Mol Neurobiol 2000;20:57-76
17. Clayton AJ, Danson S, Jolly S, et al. Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer. Br J Cancer 2004;91:639-43
18. Freilich RJ, Seidman AD, DeAngelis LM. Central nervous system progression of metastatic breast cancer in patients treated with paclitaxel. Cancer 1995;76:232-6
19. Kastritis E, Efstathiou E, Gika D, et al. Brain metastases as isolated site of relapse in patients with epithelial ovarian cancer previously treated with platinum and paclitaxel-based chemotherapy. Int J Gynecol Cancer 2006;16:994-9
20. Doolittle ND, Peereboom DM, Christoforidis GA, et al. Delivery of chemotherapy and antibodies across the blood-brain barrier and the role of chemoprotection, in primary and metastatic brain tumors: report of the Eleventh Annual Blood-Brain Barrier Consortium meeting. J Neurooncol 2007;81:81-91
21. Chou T-C, Zhang X-G, Balog A, et al. Desoxyepothilone B: an efficacious microtubule-targeted antitumor agent with a promising in vivo profi le relative to epothilone B. Proc Natl Acad Sci USA 1998;95:9642-7
22. Lichtner RB, Rotgeri A, Bunte T, et al. Subcellular distribution of epothilones in human tumor cells. Proc Natl Acad Sci USA 2001;98:11743-8
23. Rothermel J, Wartmann M, Chen T, Hohneker J. EPO906 (epothilone B): a promising novel microtubule stabilizer. Semin Oncol 2003;30(3 suppl 6):51-5
24. Lee FYF, Borzilleri R, Fairchild CR, et al. BMS-247550: a novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy. Clin Cancer Res 2001;7:1429-37
25. Villalona-Calero M, Goel S, Schaaf L, et al. First-in-human phase I trial of a novel epothilone, KOS-1584 [abstract 2003]. J Clin Oncol 2006;24
26. White JD, Carter RG, Sundermann KF, Wartmann M. Total synthesis of epothilone B, epothilone D, and cis- and trans-9,10-dehydroepothilone D. J Am Chem Soc 2001;123:5407-13
27. Klar U, Buchmann B, Schwede W, et al. Total synthesis and anti-tumor activity of ZK-EPO: the first fully synthetic epothilone in clinical development. Angew Chem Int Ed Engl 2006;45:7942-8
28. Balog A, Meng D, Kamenecka T, et al. Total synthesis of (-)-epothilone A. Angew Chem Int Ed Engl 1996;35:2801-3
29. Schinzer D, Limberg A, Bauer A, et al. Total synthesis of (-)-epothilone A. Angew Chem Int Ed Engl 1997;36:523-4
30. Yang Z, He Y, Vourloumis D, et al. Total synthesis of epothilone A: the olefin metathesis approach. Angew Chem Int Ed Engl 1997;36:166-8
31. Meng D, Bertinato P, Balog A, et al. Total syntheses of epothilones A and B. J Am Chem Soc 1997;119:10073-92
32. Nicolaou KC, Ninkovic S, Sarabia F, et al. Total synthesis of epothilones A and B via a macrolactonization-based strategy. J Am Chem Soc 1997;119:7974-91
33. Schinzer D, Bauer A, Schieber J. Syntheses of (-)-epothilone B. Chem Eur J 1999;5:2492-500
34. Hoffmann J, Vitale I, Buchmann B, et al. Improved cellular pharmacokinetics and pharmacodynamics underlie the wide anticancer activity of sagopilone. Cancer Res 2008;68:5301-8
35. Winsel S, Hammer S, Eschenbrenner J, et al. Subcellular distribution and cellular activity of the novel epothilone sagopilone (ZK-EPO). Poster 720 presented at ECCO 14;23-27 Sep 2007; Barcelona, Spain
36. Chien AJ, Moasser MM. Cellular mechanisms of resistance to anthracyclines and taxanes in cancer: intrinsic and acquired. Semin Oncol 2008;35(2 Suppl 2):S1-14
37. Fojo AT, Menefee M. Microtubule targeting agents: basic mechanisms of multidrug resistance (MDR). Semin Oncol 2005;32(6 Suppl 7):S3-8
38. Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN. Overview of resistance to systemic therapy in patients with breast cancer. Adv Exp Med Biol 2007;608:1-22
39. Horwitz SB, Cohen D, Rao S, et al. Taxol: mechanisms of action and resistance. J Natl Cancer Inst Monogr 1993;15:55-61
40. Chen YN, Mickley LA, Schwartz AM, et al. Characterization of adriamycin-resistant human breast cancer cells which display overexpression of a novel resistance-related membrane protein. J Biol Chem 1990;265:10073-80
41. Klar U, Buchmann B, Schwede W, et al. ZK-EPO, a novel epothilone derivative, exhibits significant tumor growth inhibition in a wide range of human tumor models. Poster B243 presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics; 14-18 Nov 2005; Philadelphia, PA, USA
42. Hammer S, Arnold N, Hilpert F, et al. Significant antitumour activity of the novel epothilone ZK-EPO against in vitro and in vivo models of ovarian cancer [abstract 5009]. EJC Suppl 2007;5:313
43. Winsel S, Hammer S, Buchmann B, et al. Sagopilone, a novel epothilone, inhibits tumor cell growth in preclinical models of urological cancer. Abstract 1399 presented at the American Urological Association Annual Meeting; 17-22 May 2008; Orlando, FL, USA
44. Fichtner I, Rolff J, Soong R, et al. Establishment of patient-derived non small cell lung cancer (NSCLC) xenografts as models for the identifi cation of predictive biomarkers. Cancer Res 2008; In press
45. Hammer S, Fichtner I, Becker M, et al. Comparative profiling of the novel epothilone ZK-EPO in xenografts derived from primary non-small-cell lung cancer [abstract]. AACR Meeting Abstracts 2007;3482
46. Hoffmann J, Fichtner I, Lemm M, et al. Sagopilone crosses the blood-brain barrier in vivo to inhibit brain tumor growth and metastases. Neuro Oncol 2008;In press
47. Käkönen S-M, Hoffmann J, Fichtner I, Klar U. ZK-EPO, a potent third-generation epothilone, inhibits osteoclast activity in vitro and bone metastases in vivo Poster presented at the VI International Meeting on Cancer Induced Bone Disease; 10-14 Dec 2006; San Antonio, TX, USA
48. Schmid P, Kiewe P, Kuehnhardt D, et al. A phase I study of the novel, third generation epothilone ZK-EPO in patients with advanced solid tumors [abstract 2051]. J Clin Oncol 2005;23
49. Roché H, Yelle L, Cognetti F, et al. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, as first-line therapy in patients with metastatic breast cancer previously treated with anthracycline chemotherapy. J Clin Oncol 2007;25:3415-20
50. Marupudi NI, Han JE, Li KW, et al. Paclitaxel: a review of adverse toxicities and novel delivery strategies. Expert Opin Drug Saf 2007;6:609-21
51. Arnold D, Voigt W, Kiewe P, et al. Weekly administration of ZK-EPO, a novel third-generation epothilone, in patients with refractory solid tumors: results of a Phase I trial [abstract 416P]. Ann Oncol 2006;17(Suppl 9)
52. Rustin GJ, Reed N, Jayson G, et al. Phase 2 trial of epothilone sagopilone (ZK-EPO) in patients with platinum-resistant ovarian cancer. Abstract presented at the 15th International Meeting of the European Society for Gynaecological Oncology; 28 Oct-1 Nov 2007; Berlin, Germany
53. McMeekin S, Patel R, Verschraegen C, et al. Phase I/II study of sagopilone (ZK-EPO) plus carboplatin in women with recurrent platinum-sensitive ovarian cancer. Abstract 665O presented at the 33rd ESMO Congress; 12-16 Sep 2008; Stockholm, Sweden
54. Beer TM, Smith DC, Hussain A, et al. Phase II study of first-line sagopilone combined with prednisone in patients with metastatic androgen-independent prostate cancer (AIPC). Abstract 616P presented at the 33rd ESMO Congress; 12-16 Sep 2008; Stockholm, Sweden
55. Silvani A, Fiumani A, Scaioli V, et al. A phase II study evaluating systemic sagopilone (ZK-EPO) treatment in patients with recurrent malignant gliomas. Poster presented at the 44th ASCO Annual Meeting; 30 May-2 Jun 2008; Chicago, IL, USA
56. Stupp R, Tosoni A, Bromberg JRE, et al. A phase II multicenter trial of sagopilone in patients with recurrent glioblastoma. Poster presented at the 44th ASCO Annual Meeting; 30 May-3 Jun 2008; Chicago, IL, USA
57. Gatzemeier U, von Pawel JV, Eschbach C, et al. Phase II trial of the novel epothilone ZK-EPO as second-line therapy in patients with stage IIIB or stage IV nonsmallcell lung cancer [abstract 6568]. Eur J Cancer 2007;5
58. Wenk D, DeConti RC, Urbas P, et al. Phase II trial of sagopilone (ZK-EPO), a novel epothilone, in patients with metastatic melanoma [abstract 9046]. J Clin Oncol 2008;26
59. Rass K, Tilgen W. Treatment of melanoma and nonmelanoma skin cancer. Adv Exp Med Biol 2008;624:296-318
60. Perez EA, Lerzo G, Pivot X, et al. Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine. J Clin Oncol 2007;25:3407-3414
61. Thomas E, Tabernero J, Fornier M, et al. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer. J Clin Oncol 2007;25:3399-406
62. Study to evaluate KOS-1584 in patients with advanced or metastatic stage IIIB/IV non-small cell lung cancer. Available from: ClinicalTrials.gov identifier NCT00651508; http://clinicaltrials.gov/ct2/show/ NCT00651508?term=KOS-1584&rank=1
63. Harrison M, Swanton C. Epothilones and new analogues of the microtubule modulators in taxane-resistant disease. Expert Opin Investig Drugs 2008;17:523-46
64. Yamaguchi H, Chen J, Bhalla K, Wang H-G. Regulation of Bax activation and apoptotic response to microtubule-damaging agents by p53 transcription-dependent and -independent pathways. J Biol Chem 2004;279:39431-7
65. FDA approves ixabepilone for injection (Ixempra) for two indications. Washington DC: FDA/Center for Drug Evaluation and Research, 2007. Available from: http://www.fda.gov/cder/Offices/OODP/whatsnew/ ixabepilone.htm
66. Galsky MD, Small EJ, Oh WK, et al. Multi-institutional randomized phase II trial of the epothilone B analog ixabepilone (BMS-247550) with or without estramustine phosphate in patients with progressive castrate metastatic prostate cancer. J Clin Oncol 2005;23:1439-46
67. Whitehead RP, McCoy S, Rivkin SE, et al. A Phase II trial of epothilone B analogue BMS-247550 (NSC #710428) ixabepilone, in patients with advanced pancreas cancer: A Southwest Oncology Group study. Invest New Drugs 2006;24:515-20
68. Vansteenkiste J, Lara PN Jr., Le Chevalier T, et al. Phase II clinical trial of the epothilone B analog, ixabepilone, in patients with non-small-cell lung cancer whose tumors have failed fi rst-line platinum-based chemotherapy. J Clin Oncol 2007;25:3448-55
69. Eng C, Kindler HL, Nattam S, et al. A phase II trial of the epothilone B analog, BMS-247550, in patients with previously treated advanced colorectal cancer. Ann Oncol 2004;15:928-32
70. Pavlick AC, Millward M, Farrell K, et al. A phase II study of epothilone B analog (EpoB)-BMS 247550 (NSC#710428) in stage IV malignant melanoma (MM) [abstract 7542]. J Clin Oncol ASCO Annual Meeting Proceedings;2004;22
71. Thomas ES, Gomez HL, Li RK, et al. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol 2007;25:5210-7
72. Low JA, Wedam SB, Lee JJ, et al. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in metastatic and locally advanced breast cancer. J Clin Oncol 2005;23:2726-34
73. Vahdat LT, Thomas E, Li R, et al. Phase III trial of ixabepilone plus capecitabine compared to capecitabine alone in patients with metastatic breast cancer (MBC) previously treated or resistant to an anthracycline and resistant to taxanes [abstract]. J Clin Oncol 2007;25:1006
74. Chi KN, Beardsley EK, Venner PM, et al. A phase II study of patupilone in patients with metastatic hormone refractory prostate cancer (HRPC) who have progressed after docetaxel [abstract 5166]. J Clin Oncol 2008;26
75. Hussain A, DiPaola RS, Baron AD, et al. A Phase IIa trial of weekly EPO906 in patients with hormone-refractory prostate cancer (HPRC) [abstract 4563]. J Clin Oncol ASCO Annual Meeting Proceedings;2004;22
76. Thompson JA, Swerdloff J, Escudier B, et al. Phase II trial evaluating the safety and efficacy of EPO906 in patients with advanced renal cancer [abstract 1628]. Proc Am Soc Clin Oncol 2003;22
77. Hsin K, Boyer M, Ducreux M, et al. Efficacy of patupilone in advanced local or metastatic gastric cancer: a phase IIa trial. Poster 4069 presented at the 42nd ASCO Annual Meeting; 2-6 Jun 2006; Atlanta, GA, USA
78. Abrey L, Wen P, Govindan R, et al. Patupilone for the treatment of recurrent/progressive brain metastases in patients (pts) with non-small cell lung cancer (NSCLC): an open-label phase II study. 44th ASCO Annual Meeting; 30May-3 Jun 2008; Chicago, IL, USA
79. Conlin AK, D'Andrea G, Hudis CA, et al. Phase II trial of patupilone in patients (pts) with breast cancer brain metastases (BCBM) progessing or recurring after whole brain radiation therapy (WBXRT). 44th ASCO Annual Meeting; 30 May-3 Jun 2008; Chicago, IL, USA
80. Casado E, Tabernero J, Melichar B, et al. Patupilone in chemotherapy-pretreated patients with advanced colorectal cancer (CRC) receiving nutrional support and intensive diarrhea management: a phase I multicenter trial. Poster 3593 presented at the 42nd ASCO Annual Meeting; 2-6 Jun 2006; Atlanta, GA, USA
81. Melichar B, Tabernero J, Casado E, et al. Phase I dose optimization trial of patupilone in previously treated patients (pts) with advanced colon cancer (ACC) [abstract 7110]. ASCO Annual Meeting Proceedings. J Clin Oncol 2005;23
82. Stopeck A, Moulder S, Jones S, et al. Phase I trial of KOS-1584 (a novel epothilone) using two weekly dosing schedules [abstract 2571]. ASCO Annual Meeting Proceedings Part 1. J Clin Oncol 2007;25
83. Zhong Z, Feng L, Eng S, et al. KOS-1803: a new, rationally designed epothilone analog with an improved pharmacological profile and efficacy in xenograft mouse models [abstract 1438]. AACR Meeting Abstracts; 2007
84. A Phase 1/2 study of epofolate (BMS-753493) in subjects with advanced cancer. Available from: ClinicalTrials.gov identifier NCT00550017 & NTC00546247; http://www.clinicaltrials.gov/ct2/results?term=BMS-753493
85. Winsel S, Hammer S, Mittelstaedt K, et al. Translational oncology research results strongly support the clinical evaluation of the novel epothilone ZK-EPO in breast cancer. Poster 1427 presented at the 97th AACR Annual Meeting; 2007 Apr 14-18; Los Angeles, CA, USA
86. Klar U, Hoffmann J, Lienau Ph, et al. New synthetic epothilone derivative ZK-EPO inhibits tumors generally resistant to chemotherapy. Poster 538 presented at the 16th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics; 28 Sep-1 Oct 2004; Geneva, Switzerland